{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:01:43Z","timestamp":1751774503756,"version":"3.41.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["22K15543"],"award-info":[{"award-number":["22K15543"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Nail apparatus melanoma (NAM) is a specific type of cutaneous melanoma that develops in the nail apparatus of the hands and feet. The prognosis for metastatic NAM is poor due to a lack of fully effective systemic therapies. However, the difficulty in obtaining a NAM model has hindered basic research aimed at discovering effective treatment strategies. In this study, we established a NAM cell line, named KS-NailMel-1, from a primary tumor located on the nail apparatus of the left ring finger of a 68-year-old Japanese female. The cells were successfully maintained for over 9\u00a0months, exhibiting a doubling time of 38.6\u2009\u00b1\u20091.94\u00a0h. KS-NailMel-1 displayed consistent growth, spheroid formation, and invasiveness, and was confirmed to be identical to the original tumor through short tandem repeat analyses, whole-exome sequencing, and immunohistochemistry. Western blotting of the cells demonstrated the protein expression of NECTIN4, which has recently attracted attention as a potential therapeutic target for melanoma. The KS-NailMel-1 cell line represents a valuable resource for basic and preclinical research on NAM, deepening our understanding of the tumor characteristics and facilitating the development of treatment strategies for this rare form of cancer.<\/jats:p>","DOI":"10.1007\/s13577-025-01242-7","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:06:01Z","timestamp":1748455561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KS-NailMel-1: a novel cell line of nail apparatus melanoma"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-8546","authenticated-orcid":false,"given":"Takamichi","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Tanegashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiichiro","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Ichiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Kaku-Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"1242_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485\u2013502.","journal-title":"Lancet"},{"key":"1242_CR2","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.ejca.2024.115152","volume":"215","author":"C Garbe","year":"2024","unstructured":"Garbe C, Amaral T, Peris K, European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization for Research and Treatment of Cancer (EORTC), et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics\u2014update 2024. Eur J Cancer. 2024;215:115152.","journal-title":"Eur J Cancer"},{"key":"1242_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/14656566.2022.2088279","volume":"23","author":"JM Falotico","year":"2022","unstructured":"Falotico JM, Lipner SR. The pharmacotherapeutic management of nail unit and acral melanomas. Expert Opin Pharmacother. 2022;23:1273\u201389.","journal-title":"Expert Opin Pharmacother"},{"key":"1242_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-319-22539-5_4","volume":"167","author":"N Kibbi","year":"2016","unstructured":"Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Res. 2016;167:107\u201329.","journal-title":"Cancer Treat Res"},{"key":"1242_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1586\/era.10.216","volume":"11","author":"V De Giorgi","year":"2011","unstructured":"De Giorgi V, Saggini A, Grazzini M, et al. Specific challenges in the management of subungual melanoma. Expert Rev Anticancer Ther. 2011;11:749\u201361.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1242_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2133.2006.07368.x","volume":"155","author":"A Phan","year":"2006","unstructured":"Phan A, Touzet S, Dalle S, Ronger-Savl\u00e9 S, Balme B, Thomas L. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006;155:561\u20139.","journal-title":"Br J Dermatol"},{"key":"1242_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1365-2133.2000.03651.x","volume":"143","author":"C Kuchelmeister","year":"2000","unstructured":"Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in Caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol. 2000;143:275\u201380.","journal-title":"Br J Dermatol"},{"key":"1242_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10552-008-9221-y","volume":"20","author":"E Nagore","year":"2009","unstructured":"Nagore E, Pereda C, Botella-Estrada R, Requena C, Guill\u00e9n C. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control. 2009;20:115\u20139.","journal-title":"Cancer Causes Control"},{"key":"1242_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jdv.17975","volume":"36","author":"CC Darmawan","year":"2022","unstructured":"Darmawan CC, Ohn J, Mun JH, et al. Diagnosis and treatment of nail melanoma: a review of the clinicopathologic, dermoscopic, and genetic characteristics. J Eur Acad Dermatol Venereol. 2022;36:651\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1242_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","volume":"145","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986\u20132005. Arch Dermatol. 2009;145:427\u201334.","journal-title":"Arch Dermatol"},{"key":"1242_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/jamadermatol.2021.2215","volume":"157","author":"MA Marchetti","year":"2021","unstructured":"Marchetti MA, Adamson AS, Halpern AC. Melanoma and racial health disparities in black individuals-facts, fallacies, and fixes. JAMA Dermatol. 2021;157:1031\u20132.","journal-title":"JAMA Dermatol"},{"key":"1242_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/DAD.0000000000001106","volume":"40","author":"OW Nevares-Pomales","year":"2018","unstructured":"Nevares-Pomales OW, Sarriera-Lazaro CJ, Barrera-Llaurador J, et al. Pigmented lesions of the nail unit. Am J Dermatopathol. 2018;40:793\u2013804.","journal-title":"Am J Dermatopathol"},{"key":"1242_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jaad.2018.02.019","volume":"79","author":"M Lee","year":"2018","unstructured":"Lee M, Yoon J, Chung YJ, et al. Whole-exome sequencing reveals differences between nail apparatus melanoma and acral melanoma. J Am Acad Dermatol. 2018;79:559-61.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1242_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jid.2017.08.022","volume":"138","author":"AM Haugh","year":"2018","unstructured":"Haugh AM, Zhang B, Quan VL, et al. Distinct patterns of acral melanoma based on site and relative sun exposure. J Invest Dermatol. 2018;138:384\u201393.","journal-title":"J Invest Dermatol"},{"key":"1242_CR15","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell F, Wilmott JS, Johansson PA, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020;11:5259.","journal-title":"Nat Commun"},{"key":"1242_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjd.15803","volume":"178","author":"Y Teramoto","year":"2018","unstructured":"Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018;178:443\u201351.","journal-title":"Br J Dermatol"},{"key":"1242_CR17","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.18632\/oncotarget.27642","volume":"11","author":"A Borkowska","year":"2020","unstructured":"Borkowska A, Szumera-Cie\u0107kiewicz A, Spa\u0142ek M, et al. Mutation profile of primary subungual melanomas in Caucasians. Oncotarget. 2020;11:2404\u201313.","journal-title":"Oncotarget"},{"key":"1242_CR18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jaad.2021.06.847","volume":"86","author":"H Yoo","year":"2022","unstructured":"Yoo H, Kim H, Kwon ST, et al. Tumor invasion in the hyponychium is associated with distant metastasis and poor prognosis in subungual melanoma: a histologic landscape of 44 cases. J Am Acad Dermatol. 2022;86:1027\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"1242_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/1346-8138.15151","volume":"47","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Asai J, Igaki H, et al. Japanese dermatological association guidelines: outlines of guidelines for cutaneous melanoma 2019. J Dermatol. 2020;47:89\u2013103.","journal-title":"J Dermatol"},{"key":"1242_CR20","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1097\/PAS.0b013e318073c600","volume":"31","author":"KB Tan","year":"2007","unstructured":"Tan KB, Moncrieff M, Thompson JF, et al. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg Pathol. 2007;31:1902\u201312.","journal-title":"Am J Surg Pathol"},{"key":"1242_CR21","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.bjps.2017.08.001","volume":"70","author":"DJ Reilly","year":"2017","unstructured":"Reilly DJ, Aksakal G, Gilmour RF, et al. Subungual melanoma: management in the modern era. J Plast Reconstr Aesthet Surg. 2017;70:1746\u201352.","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"1242_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.amjsurg.2007.03.010","volume":"195","author":"T Cohen","year":"2008","unstructured":"Cohen T, Busam KJ, Patel A, Brady MS. Subungual melanoma: management considerations. Am J Surg. 2008;195:244\u20138.","journal-title":"Am J Surg"},{"key":"1242_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.det.2020.12.006","volume":"39","author":"J Zhang","year":"2021","unstructured":"Zhang J, Yun SJ, McMurray SL, Miller CJ. Management of nail unit melanoma. Dermatol Clin. 2021;39:269\u201380.","journal-title":"Dermatol Clin"},{"key":"1242_CR24","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","volume":"215","author":"C Garbe","year":"2024","unstructured":"Garbe C, Amaral T, Peris K, European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization for Research and Treatment of Cancer (EORTC), et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2024. Eur J Cancer. 2024;215:115153.","journal-title":"Eur J Cancer"},{"key":"1242_CR25","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm12062203","volume":"12","author":"T Ito","year":"2023","unstructured":"Ito T, Hashimoto H, Kaku-Ito Y, Tanaka Y, Nakahara T. Nail apparatus melanoma: current management and future perspectives. J Clin Med. 2023;12:2203.","journal-title":"J Clin Med"},{"key":"1242_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-018-0676-z","volume":"20","author":"M Furue","year":"2018","unstructured":"Furue M, Ito T, Wada N, et al. Melanoma and immune checkpoint inhibitors. Curr Oncol Rep. 2018;20:29.","journal-title":"Curr Oncol Rep"},{"key":"1242_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"1242_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127\u201337.","journal-title":"J Clin Oncol"},{"key":"1242_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med"},{"key":"1242_CR30","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol. 2022;40:4178\u201388.","journal-title":"J Clin Oncol"},{"key":"1242_CR31","doi-asserted-by":"publisher","first-page":"15720","DOI":"10.3390\/ijms232415720","volume":"23","author":"T Fujimura","year":"2022","unstructured":"Fujimura T, Muto Y, Asano Y. Immunotherapy for melanoma: the significance of immune checkpoint inhibitors for the treatment of advanced melanoma. Int J Mol Sci. 2022;23:15720.","journal-title":"Int J Mol Sci"},{"key":"1242_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11864-018-0560-y","volume":"19","author":"Y Nakamura","year":"2018","unstructured":"Nakamura Y, Fujisawa Y. Diagnosis and management of acral lentiginous melanoma. Curr Treat Options Oncol. 2018;19:42.","journal-title":"Curr Treat Options Oncol"},{"key":"1242_CR33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","volume":"31","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Namikawa K, Yoshino K, et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020;31:1198\u2013206.","journal-title":"Ann Oncol"},{"key":"1242_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2020.12.021","volume":"145","author":"Y Fujisawa","year":"2021","unstructured":"Fujisawa Y, Ito T, Kato H, et al. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: an analysis of 112 cases. Eur J Cancer. 2021;145:210\u201320.","journal-title":"Eur J Cancer"},{"key":"1242_CR35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/CMR.0000000000000688","volume":"30","author":"BN Holman","year":"2020","unstructured":"Holman BN, Van Gulick RJ, Amato CM, et al. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 2020;30:562\u201373.","journal-title":"Melanoma Res"},{"key":"1242_CR36","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135\u201347.","journal-title":"N Engl J Med"},{"key":"1242_CR37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jid.2017.11.017","volume":"138","author":"KR Moon","year":"2018","unstructured":"Moon KR, Choi YD, Kim JM, et al. Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: common mutated genes show distinct cytomorphological features. J Invest Dermatol. 2018;138:933\u201345.","journal-title":"J Invest Dermatol"},{"key":"1242_CR38","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.jaad.2020.03.109","volume":"83","author":"Y Lim","year":"2020","unstructured":"Lim Y, Yoon D, Lee DY. Novel mutations identified by whole-exome sequencing in acral melanoma. J Am Acad Dermatol. 2020;83:1792\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"1242_CR39","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s13577-023-00951-1","volume":"36","author":"T Ito","year":"2023","unstructured":"Ito T, Tanaka Y, Ichiki T, Kaku-Ito Y, Nakahara T. KS-EMPD-1: a novel cell line of primary extramammary Paget\u2019s disease. Hum Cell. 2023;36:1813\u201329.","journal-title":"Hum Cell"},{"key":"1242_CR40","doi-asserted-by":"publisher","first-page":"1483450","DOI":"10.3389\/fmed.2024.1483450","volume":"11","author":"T Ito","year":"2024","unstructured":"Ito T, Tanaka Y, Kaku-Ito Y, et al. KS-cSCC-1 and KS-cSCC-2: two novel cutaneous squamous cell carcinoma cell lines established from Japanese patients. Front Med (Lausanne). 2024;11:1483450.","journal-title":"Front Med (Lausanne)"},{"key":"1242_CR41","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/pcmr.12996","volume":"34","author":"R Hu","year":"2021","unstructured":"Hu R, Zhao S, Su J, Chen X, Yin M. Establishment of cultured primary acral melanoma cells and animal models for Chinese patients. Pigment Cell Melanoma Res. 2021;34:1131\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1242_CR42","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.3390\/ijms21165891","volume":"21","author":"M Murata","year":"2020","unstructured":"Murata M, Ito T, Tanaka Y, Kaku-Ito Y, Furue M. NECTIN4 expression in extramammary Paget\u2019s disease: implication of a new therapeutic target. Int J Mol Sci. 2020;21:5891.","journal-title":"Int J Mol Sci"},{"key":"1242_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biomedicines9040355","volume":"9","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Murata M, Oda Y, Furue M, Ito T. Nectin cell adhesion molecule 4 (NECTIN4) expression in cutaneous squamous cell carcinoma: a new therapeutic target? Biomedicines. 2021;9:355.","journal-title":"Biomedicines"},{"key":"1242_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1684\/ejd.2022.4241","volume":"32","author":"T Ito","year":"2022","unstructured":"Ito T, Hashimoto H, Tanaka Y, et al. NECTIN4 expression in sebaceous and sweat gland carcinoma. Eur J Dermatol. 2022;32:181\u20136.","journal-title":"Eur J Dermatol"},{"key":"1242_CR45","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/ijms22020976","volume":"22","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Murata M, Shen CH, Furue M, Ito T. NECTIN4: a novel therapeutic target for melanoma. Int J Mol Sci. 2021;22:976.","journal-title":"Int J Mol Sci"},{"key":"1242_CR46","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1038\/s41598-022-07727-x","volume":"12","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Murata M, Tanegashima K, Oda Y, Ito T. Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma. Sci Rep. 2022;12:4031.","journal-title":"Sci Rep"},{"key":"1242_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11864-022-00940-w","volume":"23","author":"H Hashimoto","year":"2022","unstructured":"Hashimoto H, Tanaka Y, Murata M, Ito T. Nectin-4: a novel therapeutic target for skin cancers. Curr Treat Options Oncol. 2022;23:578\u201393.","journal-title":"Curr Treat Options Oncol"},{"key":"1242_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41420-023-01358-5","volume":"9","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Ito T, Kaku-Ito Y, et al. Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma. Cell Death Discov. 2023;9:54.","journal-title":"Cell Death Discov"},{"key":"1242_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15049","volume":"33","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Ito T, Murata M, et al. NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease. Exp Dermatol. 2024;33: e15049.","journal-title":"Exp Dermatol"},{"key":"1242_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/jcm9030618","volume":"9","author":"M Murata","year":"2020","unstructured":"Murata M, Ito T, Tanaka Y, Yamamura K, Furue K, Furue M. OVOL2-mediated ZEB1 downregulation may prevent promotion of actinic keratosis to cutaneous squamous cell carcinoma. J Clin Med. 2020;9:618.","journal-title":"J Clin Med"},{"key":"1242_CR51","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ajpath.2015.12.013","volume":"186","author":"T Ito","year":"2016","unstructured":"Ito T, Tsuji G, Ohno F, et al. Activation of the OVOL1-OVOL2 axis in the hair bulb and in pilomatricoma. Am J Pathol. 2016;186:1036\u201343.","journal-title":"Am J Pathol"},{"key":"1242_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.25242","volume":"127","author":"A Capes-Davis","year":"2010","unstructured":"Capes-Davis A, Theodosopoulos G, Atkin I, et al. Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 2010;127:1\u20138.","journal-title":"Int J Cancer"},{"key":"1242_CR53","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston DR, Davis M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res. 2017;23:3489\u201398.","journal-title":"Clin Cancer Res"},{"key":"1242_CR54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/jclinpath-2018-205653","volume":"72","author":"AJ Colebatch","year":"2019","unstructured":"Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: its function and dysregulation in cancer. J Clin Pathol. 2019;72:281\u20134.","journal-title":"J Clin Pathol"},{"key":"1242_CR55","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/s41379-020-0565-5","volume":"33","author":"NS Ramani","year":"2020","unstructured":"Ramani NS, Aung PP, Gu J, et al. TERT amplification but not activation of canonical Wnt\/\u03b2-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Modern Pathol. 2020;33:2067\u201374.","journal-title":"Modern Pathol"},{"key":"1242_CR56","doi-asserted-by":"publisher","first-page":"8420850","DOI":"10.5858\/arpa.2020-0330-OA","volume":"145","author":"WC Cho","year":"2021","unstructured":"Cho WC, Wang W, Milton DR, et al. Telomerase reverse transcriptase protein expression is more frequent in acral lentiginous melanoma than in other types of cutaneous melanoma. Arch Pathol Lab Med. 2021;145:8420850.","journal-title":"Arch Pathol Lab Med"},{"key":"1242_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114208","volume":"208","author":"P Jansen","year":"2024","unstructured":"Jansen P, Galetzka W, Lodde GC, et al. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (\u201cTriple\u201d) wild type melanomas. Eur J Cancer. 2024;208: 114208.","journal-title":"Eur J Cancer"},{"key":"1242_CR58","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/cup.14290","volume":"49","author":"AT Rothrock","year":"2022","unstructured":"Rothrock AT, Torres-Cabala CA, Milton DR, et al. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions. J Cutan Pathol. 2022;49:859\u201367.","journal-title":"J Cutan Pathol"},{"key":"1242_CR59","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/PAS.0000000000001878","volume":"46","author":"G Santandrea","year":"2022","unstructured":"Santandrea G, Valli R, Zanetti E, et al. Comparative analysis of PRAME expression in 127 acral and nail melanocytic lesions. Am J Surg Pathol. 2022;46:579\u201390.","journal-title":"Am J Surg Pathol"},{"key":"1242_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13000-022-01218-3","volume":"17","author":"YJ Kim","year":"2022","unstructured":"Kim YJ, Jung CJ, Na H, et al. Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit. Diagn Pathol. 2022;17:41.","journal-title":"Diagn Pathol"},{"key":"1242_CR61","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/cancers14030778","volume":"14","author":"C Esnault","year":"2022","unstructured":"Esnault C, Schrama D, Houben R, et al. Antibody-drug conjugates as an emerging therapy in oncodermatology. Cancers (Basel). 2022;14:778.","journal-title":"Cancers (Basel)"},{"key":"1242_CR62","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s11864-022-01018-3","volume":"23","author":"R Goodman","year":"2022","unstructured":"Goodman R, Johnson DB. Antibody-drug conjugates for melanoma and other skin malignancies. Curr Treat Options Oncol. 2022;23:1428\u201342.","journal-title":"Curr Treat Options Oncol"},{"key":"1242_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14:20.","journal-title":"J Hematol Oncol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01242-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:02:41Z","timestamp":1751698961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01242-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1242"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01242-7","relation":{},"ISSN":["1749-0774"],"issn-type":[{"type":"electronic","value":"1749-0774"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Kyushu University Hospital (Approval no. 21050\u201300, approved on November 10 th, 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient before inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"112"}}